Aarti Drugs Deepens Latin American Push with New Chilean Step-Down Subsidiary

Aarti Drugs Limited ( (IN:AARTIDRUGS) ) has issued an announcement.

Aarti Drugs Limited has expanded its international footprint in the pharmaceutical sector through the incorporation of Tripharma Chile SpA as an overseas wholly owned subsidiary of its unit Pinnacle Chile SpA, making Tripharma a step-down subsidiary of the Indian drug maker. Tripharma Chile SpA, established in Chile with a share capital of 10,00,000 Chilean pesos, will focus on marketing formulation drugs and participating in both tender and private markets, reinforcing Aarti Drugs’ strategic push into Latin American healthcare markets.

The new Chilean subsidiary is fully funded through cash contribution and will be entirely owned by Pinnacle Chile SpA, ensuring 100% indirect control by Aarti Drugs Limited over its operations. By aligning Tripharma Chile SpA’s business model with that of its parent entities, the company aims to deepen its commercial reach in Chile’s pharmaceutical industry, potentially enhancing its competitive positioning and opening new revenue streams in overseas markets.

More about Aarti Drugs Limited

Aarti Drugs Limited is an Indian pharmaceutical company engaged in the production and marketing of formulation drugs. Through its subsidiaries, it focuses on serving international markets, aligning overseas operations with its core pharmaceutical business and expanding its presence in regulated and tender-driven markets such as Chile.

Average Trading Volume: 7,095

Technical Sentiment Signal: Sell

Current Market Cap: 33.5B INR

See more data about AARTIDRUGS stock on TipRanks’ Stock Analysis page.